Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to accelerate large‑scale AI models for protein design, the company said. Profluent will expand its platform beyond genome editors into antibodies, enzymes and bespoke proteins for therapeutics, agriculture and industrial bioscience, and noted existing partnerships with Integrated DNA Technologies and Revvity. The financing and backing from high‑profile investors signal continued venture capital interest in AI‑driven protein engineering and the race to commercialize end‑to‑end design and delivery workflows.